May 9th 2024
VYNE expects to enroll the first patient with vitiligo in the phase 2b trial for VYN201 in the second quarter of 2024.
Payers Reveal Most Significant Factors Impacting Biosimilar Coverage Decisions
July 3rd 2023It was found that cancer treatment, pediatric population, and coverage restriction of reference products were revealed as some of the strongest factors associated with biosimilar coverage decisions by US commercial health plans relative to reference products.